IL2RA and pancreatic ductal adenocarcinoma: 2.4. Validation of Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Marker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal Adenocarcinoma